매출 비중은 nine months ended July 31, 2026 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.
Infinity III liquid chromatography systems
Instruments that separate the substances in a liquid sample so a laboratory can identify and measure them.
8890B and 8860B gas chromatographs
Instruments that separate and measure substances that can be turned into gas, including chemicals in fuels and contaminants in food.
9500 triple-quadrupole inductively coupled plasma mass spectrometer
An instrument that measures very small amounts of metals and other elements, including in samples used in semiconductor manufacturing.
Altura liquid chromatography columns
Replaceable tubes that separate substances inside a chromatography system, including in testing of protein-based and nucleic-acid medicines.
Dako Omnis pathology systems
Automated instruments and related supplies used by clinical laboratories to stain and examine tissue samples for cancer diagnosis.
Oligonucleotide contract manufacturing
Manufacturing of short DNA- or RNA-like drug ingredients for pharmaceutical customers, from development through commercial production.
Agilent makes instruments that help laboratories identify and measure the chemicals, cells and other materials in samples. It also sells the supplies used with those instruments, maintains lab equipment, and provides software for collecting and managing test results. For drug companies, Agilent also makes ingredients used in some medicines and manufactures certain drug materials under contract.
Agilent Technologies, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
The themes Agilent Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$173.02-2.2%11월 12일 종가
다음 실적 발표: 2026년 11월 23일 · 장 마감 후
2026년 7월 31일까지의 수치 (2026년 9월 1일 제출 10-Q 기준)
Agilent sells laboratory supplies and maintenance services, plus scientific instruments, to pharmaceutical companies, hospitals, research labs and testing laboratories.
회사 전망: 2026 회계연도 매출 US$7.5B~US$7.5B — 전년 대비 7.9% 증가
Grade B+
주가 아래 띠는 각 날짜의 등급으로, 그 시점까지 공개된 자료만으로 산출했습니다.
Agilent Technologies, Inc.의 등급 이력 40개 분기 중 2개를 표시하고 있습니다. 나머지 38개는 2016년 12월까지 거슬러 올라갑니다.